Abstract
<title>Abstract</title> <p> <bold>Background</bold> Fibrotic interstitial lung diseases (ILDs) are chronic, progressive disorders characterised by marked symptom burden and poor prognosis. The Treatable Traits (TT) precision medicine model has demonstrated improved health outcomes in airway diseases; however, its role in ILD has not previously been studied. <bold>Objective</bold> This randomised controlled trial aims to compare the clinical efficacy and cost-effectiveness of a treatable traits model of care (TTRILD) compared to standard care in people with ILD. <bold>Methods</bold> A total of 110 participants with fibrotic ILD will be recruited from two tertiary ILD centres and randomised 1:1 to either the TTRILD intervention or standard care. Participants in the intervention arm will receive multidimensional assessment and TT-targeted management delivered through a multidisciplinary clinic, with specific interventions provided by allied health professionals. The primary outcome will be change in the King’s Brief Interstitial Lung Disease (K-BILD) score at 6 months, reflecting health-related quality of life. <bold>Discussion</bold> This study aims to improve quality of life in people with ILD by assessing the impact of a treatable traits multidisciplinary model of care. Findings are expected to provide key insights into ILD management pathways and inform strategies to reduce symptom burden and optimise patient-centred outcomes. <bold>Trial registration</bold> ClinicalTrials.gov identifier: NCT06626438. Registered on 3 October 2024. </p>